Long non-coding RNA DLX6-AS1 acts as an oncogene by targeting miR-613 in ovarian cancer
Authors: Q You
C-F Gong
H-Y Shi
X-Y Tian
S Li
Journal: European Review for Medical and Pharmacological Sciences (2019)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: lncRNA; DLX6-AS1; ovarian cancer; metastasis; progression
Affiliations: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, China. .

Abstract:  Objective: Recently, long non-coding RNAs (lncRNAs) have been extensively studied for their role in tumor progression. This work explored the role of lncRNA DLX6-AS1 in mediating the development of ovarian cancer (OC). Patients and methods: DLX6-AS1 expression was detected by Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) in OC tissues. Moreover, wound healing assay and transwell assay were performed to detect the effect of DLX6-AS1 on the metastasis of OC. Furthermore, the underlying mechanism of DLX6-AS1 in mediating the progression of OC was explored through the Dual-Luciferase reporter gene assay and RNA immunoprecipitation assay (RIP). Results: DLX6-AS1 expression was higher in OC samples than that in the adjacent ones. Moreover, cell migration and invasion were suppressed after DLX6-AS1 knockdown in vitro. Conversely, cell migration and invasion were promoted by overexpressed DLX6-AS1. Moreover, the expression of microRNA-613 (miR-613) was upregulated via knockdown of DLX6-AS1, but was downregulated after overexpression of DLX6-AS1. Furthermore, the Luciferase reporter gene assay and RIP assay showed that miR-613 was a direct target of MIAT in DLX6-AS1 in OC tissues. Conclusions: DLX6-AS1 could enhance migration and invasion of OC cells via targeting miR-613, which might serve as a potential therapeutic target in OC. 

Retracted: Yes

PubPeer comments:
 This paper is one of a set of 121 papers that all contain images from the same library of about 100 photos and plots. This is unexpected, because each paper has different authors and different affiliations, with little to no overlap, and describes different cancer types and molecules. It would be very hard to explain how authors from different labs would all obtain the same photo. Therefore, the papers might have all be derived from the same source, such as a paper mill that sells ready-to-be-published papers. This  Stock Photo paper set has been described in more detail on my blog post, https: scienceintegritydigest.com 2020 07 05 the-stock-photo-paper-mill and in a Wall Street Journal article by Eva Xiao (currently behind a paywall): https: www.wsj.com articles chinese-research-papers-raise-doubts-fueling-global-questions-about-scientific-integrity-11593939600 The vast majority (113 121) of the papers were published in the same journal, European Review for Medical and Pharmacological Sciences (ERMPS). A link to the full set of papers can be found here: https: docs.google.com spreadsheets d 172RWS18w1lTNJ9Nnj80fuXXTqTm4fGkoK0sdYyvKE3g edit?usp=sharing All papers have been reported to the journal editors on July 2, 2020. , 
 [Retracted by the publisher] . Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, u201cLong non-coding RNA DLX6-AS1 acts as an oncogene by targeting miR-613 in ovarian cancer, by Q. You, H.-Y. Shi, C.-F. Gong, X.-Y. Tian, S. Li, published in Eur Rev Med Pharmacol Sci 2019;23 (15): 6429-6435u2013DOI: 10.26355 eurrev_201908_18524u2013PMID: 31378881u201d has been withdrawn. The Publisher apologizes for any inconvenience this may cause. ![file] , 
 http: www.most.gov.cn zxgz kycxjs kycxgzdt 202201 t20220127_179206.html Google Translated Date: January 27, 2022 14:44 Source: Ministry of Science and Technology u3000u300028. The paper  Long non-coding RNA DLX6-AS1 acts as an oncogene by targeting miR-613 in ovarian cancer by You Qi as the first author and corresponding author of the First Affiliated Hospital of Harbin Medical University. After investigation, it was found that the paper had buying and selling papers and improper labeling. You Qi will be dealt with as follows: order to withdraw the manuscript, admonish the scientific research integrity and talk, withdraw the scientific research award for the paper, and withdraw all the bonus, cancel her application for scientific and technological plan (special projects, funds, etc.) projects and award qualifications for 5 years, and cancel the academic degree graduate student. Enrollment qualifications for 3 years, cancel the qualifications for promotion for 3 years, and conduct self-examination on the research of other members of the research group within 1 year to avoid similar incidents. u3000u3000(Notification link: https: www.hrbmu.edu.cn kyc info 1026 1321.htm) ,